Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue 3, 1998, Pages 252-259

  Ferry, James J ^a   Herman, Beth D ^a   Carel, Barbara J ^a   Carlson, Glenn F ^a,b   Batts, Donald H ^a  

^a PFIZER INC   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Delavirdine; Drug interaction; Healthy volunteers; Indinavir; Pharmacokinetics

Indexed keywords

DELAVIRDINE; INDINAVIR; PROTEINASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINASE INHIBITION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032125527     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199807010-00009     Document Type: Article

References (22)

1. Dykeman MC, Wallace R, Ferrell P, Jasek J, Tortorice PV. Drug interactions: how they affect people living with HIV/AIDS. J Assoc Nurses AIDS Care 1996;7:67-79.
2. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997;41:654-60.
3. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996;10:485-92.
4. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997;277:145-53.
5. de Jong MD, Boucher CAB, Galasso GJ, et al. Consensus symposium on combined antiviral therapy. Antiviral Res 1995;29:5-29.
6. Dueweke TJ, Kezdy FJ, Waszak GA, Deibel MR. Tarpley WG. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem 1992;267:27-30.
7. Romero DL, Busso M, Tan CK, et al. Non-nucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1991;88:8806-10.
8. Vasudevachari MB, Battista C, Lane HC, et al. Prevention of the spread of HIV-1 infection with non-nucleoside reverse transcriptase inhibitors. Virology 1992;190:269-7.
9. Althaus IW, Chou JJ, Gonzales AJ, et al. Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E. Biochem Pharmacol 1994;47: 2017-28.
10. Cheng C-L, Smith DE, Carver PL, et al. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther 1997;61:531-43.
11. Cox SR, Batts DH, Ward P, et al. Escalating single and multiple dose safety, tolerance and pharmacokinetics (PK) of delavirdine mesylate (DLV, U-90152S) in normal volunteers. In Program and abstracts of the First National Conference on Human Retroviruses and Related Infections, Washington, DC, December 1993.
12. 3, who are maintained on a stable dose of AZT. In Program and abstracts of the First National Conference on Human Retroviruses and Related Infections, Washington, DC, December 1993.
13. Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther 1997;61:544-53.
14. Borin MT, Chambers JH, Carel BJ, Freimuth WW, Aksentijevich S, Piergies AA. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral Res 1997;35:53-63.
15. McCrea J, Woolf E, Sterrett A, et al. Effects of ketoconazole and other P-450 inhibitors on the pharmacokinetics of indinavir. Pharm Res 1996;13:S-485.
16. Bjosson T, Chiou R, Deutsch P, et al. Pharmacokinetics of indinavir. Phcirm Res 1996;13:S-185.
17. Staton BA, Johnson MG, Friis JM, Adams WJ. Simple, rapid, and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma. J Chromatogr 1995;668:99-106.
18. Woolf E, Au T, Haddix H, Matuszewski B. Determination of L-735 524, a human immunodeficiency virus protease inhibitor, in plasma and urine via high-performance liquid chromatography with column switching. J Chromatogr 1995;692:45-52.
19. Borin MT, Cox SR, Herman BD, Carel BJ, Anderson RD, Freimuth WW. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in HIV-positive patients. Antimcrob Agents Chemother 1997;41:1892-97.
20. Cox SR, Borin MT, Driver MR, Levy B, Freimuth WW. Effect of clarithromycin on the steady-state pharmacokinetics of delavirdine in HIV-1 patients. Second National Conference on Human Retroviruses and Related Infections, Washington, DC, January 29-February 2, 1995.
21. Cox SR, Ferry JJ, Batts DH, et al. Delavirdine (D) and marketed protease inhibitors (Pis): pharmacokinetic (PK) interaction studies in healthy volunteers (abstract 372). Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
22. Cox SR, Schneck DW, Herman BD, et al. Delavirdine (DLV) and nelfinavir (NFV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers (abstract 573). Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.